FAQ

Liposomal Eribulin Mesylate

Known as: E7389 Liposomal Formulation, E7389-LF 
A liposome-encapsulated formulation of the mesylate salt form of eribulin, a synthetic, macrocyclic ketone analogue of halichondrin B, a substance… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2013
012320092013

Related topics

Related topics

4 relations
Microtubule ProcessMicrotubulesNegative Regulation of MitosisTubulin

Related mentions per year

Related mentions per year

1953-2018
1960198020002020
Liposomal Eribulin Mesylate
Microtubules
Tubulin
Negative Regulation of Mitosis
Microtubule Process

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.
Eribulin mesylate (E7389), a tubulin and microtubule inhibitor, has been approved to treat metastatic breast cancer in certain… (More)
Is this relevant?
2009
2009
New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: reductive cyclization and oxy-Michael cyclization approaches.
Cr-mediated coupling reactions are usually achieved with a slight excess of a given nucleophile. To develop a cost-effective use… (More)
Is this relevant?
2009
2009
Second generation synthesis of C27-C35 building block of E7389, a synthetic halichondrin analogue.
A practical method is reported to synthesize E7389 C27-C35 building block 13 from 1,2-O-isopropylidene-alpha-D-5-deoxyglucurono-6… (More)
  • figure 1
  • figure 2
Is this relevant?
2009
2009
New syntheses of E7389 C14-C35 and halichondrin C14-C38 building blocks: double-inversion approach.
With sequential use of catalytic asymmetric Cr-mediated coupling reactions, E7389 C14-C35 and halichondrin C14-C38 building… (More)
  • figure 1
Is this relevant?